Deepbridge launches Life Sciences EIS

Tax-efficient investment specialist Deepbridge has today (27 February 2017) announced the launch of the Deepbridge Life Sciences EIS proposition.

Following on from the success of the Deepbridge Life Sciences Seed EIS, which has to date raised £5.2m and will have funded over 30 seed-stage companies by the end of the tax year, Deepbridge has launched the Deepbridge Life Sciences EIS to provide much-needed commercialisation funding for healthcare and medical technology innovation, whilst offering investors the potential tax reliefs available under the Enterprise Investment Scheme.

Deepbridge manages in excess of £60m of funds, predominantly utilising the Government’s EIS and SEIS initiatives.

Deepbridge currently also operates the evergreen Deepbridge Technology Growth EIS and has remaining capacity for deployment in the 2016/17 tax year in both the Deepbridge Technology Growth EIS and Deepbridge Life Sciences EIS.

Ian Warwick, Managing Partner at Deepbridge Capital, commented:

“The Deepbridge team only invests in sectors in which they have significant experience, which is why our EIS and SEIS propositions are sector focused on the technology or life sciences sectors.  Investing in life sciences, healthcare, biotechnology and medical technology requires specific sector expertise and investors should carefully consider the experience of the team behind any such investment.

“Our approach, led by Head of Life Sciences Dr Savvas Neophytou, of identifying life sciences innovations with the potential opportunity for high growth and working closely with those companies to develop leading-edge businesses, ultimately aiming to generate real returns to our investors, is appreciated by advisers and investors alike who want to know where and now their money is being invested.  Any company we invest in has to be an appealing investment opportunity regardless of any tax-reliefs.  The tax-reliefs potentially available under the Enterprise Investment Scheme should be considered risk mitigation for investors rather than our driver for investing.

“It is predicted that the global healthcare IT sector alone could be worth $202bn per annum by 2025.  With the UK seen as one of the world’s leading Life Sciences innovators, the Government’s Strategy for UK Life Sciences predicts this market to be a particular specialism for the UK but highlights the need for ongoing funding.”

Ian Warwick, Managing Partner at Deepbridge